CANY
PRVB

Caxton Associates (New York)’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Caxton Associates (New York)’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,198
Closed -$119K – 761
2021
Q4 		$119K Buy
+21,198
New +$135K 0.01% 518

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Caxton Associates (New York)'s PRVB Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2022, closing a stake of 21,198 shares — an estimated $119K sold.

Caxton Associates (New York) first reported a position in PRVB in Q4 2021 and held it in 1 quarter. The position peaked at $119K in Q4 2021. 113 funds tracked by Wall St. Rank hold PRVB as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 21,198 Provention Bio, Inc. Common Stock shares in Q1 2022, an estimated $119K.
  • Caxton Associates (New York) first reported a position in Provention Bio, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Provention Bio, Inc. Common Stock position peaked at $119K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.